Abstract
From numerous studies, it is known about the role of SGLT-2 inhibitors in reducing glycemia, cardio- and nephroprotection in patients with type 2 diabetes (DM2). SGLT-1 has been studied less, the management and activity of which may also be the key to compensation of type 2 diabetes, chronic diseases of the heart, kidneys and other organs and tissues. At the moment, inhibition of SGLT-1 in humans can only be achieved by using combined inhibitors of SGLT-1/SGLT-2. Drugs with selective inhibition of SGLT-1 are actively studied in animals and in vitro studies. This review is devoted to the principles of the action of SGLT-1, the effect of inhibition of SGLT-1 on pathological conditions, and also evaluation of the prospects for the use of SGLT-1i in humans.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
